Biologics can achieve clinically important risk reductions in eosinophilic airway disease – as long as you give them to the right patients with the right pathology and look at the right outcome measures, an international expert says. Speaking at a respiratory forum in Melbourne Professor Ian Pavord, a consultant respiratory physician at the University of ...
Is there a future for biologics in COPD and asthma?
Sponsored by A. Menarini Pty Ltd
By Helen Signy
21 Jul 2016